Cargando…

Does HER2/neu overexpression in breast cancer influence adjuvant chemotherapy and hormonal therapy choices by Ontario physicians? A physician survey

Detalles Bibliográficos
Autores principales:	Myers, J.A., DeBoer†, G., Warner, E.
Formato:	Texto
Lenguaje:	English
Publicado:	Multimed Inc. 2006
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1891167/ https://www.ncbi.nlm.nih.gov/pubmed/17576435

Ejemplares similares

Adjuvant Hormonal Therapy in Postmenopausal Women with Breast Cancer: Physician's Choices
por: Shaikh, Asim Jamal, et al.
Publicado: (2012)

Freund's vaccine adjuvant promotes Her2/Neu breast cancer
por: Cotroneo, Michelle S, et al.
Publicado: (2009)

Multispecialty physician networks in Ontario
por: Stukel, Therese A, et al.
Publicado: (2013)

Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
por: DiGiovanna, M. P., et al.
Publicado: (1996)

Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status
por: Brodowicz, T, et al.
Publicado: (2001)

HER-2/neu oncogene: what does amplification mean?
por: Pavy, J. J., et al.
Publicado: (1993)

Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8(+) T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice
por: Chen, Y, et al.
Publicado: (2011)

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
por: Santin, Alessandro D., et al.
Publicado: (2016)

HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder
por: Latif, Z, et al.
Publicado: (2003)

TOPOIIα and HER-2/neu overexpression/amplification in Barrett’s oesophagus, dysplasia and adenocarcinoma
por: Rossi, Elisa, et al.
Publicado: (2010)

cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine Carcinosarcoma
por: Semiz, Huseyin Salih, et al.
Publicado: (2023)

Primary Care Physician Use and Frequency of Visits Among Physicians in Ontario, Canada
por: Rhodes, Emily, et al.
Publicado: (2022)

Potential for patient-physician language discordance in Ontario
por: Sears, Jennifer, et al.
Publicado: (2013)

Ontario Geriatric Specialist Physician Resources 2018
por: Borrie, Michael, et al.
Publicado: (2020)

Disparities in Physician Compensation by Gender in Ontario, Canada
por: Steffler, Mitch, et al.
Publicado: (2021)

Physician ratings of physician assistant competencies and their experiences and satisfaction working with physician assistants: Results from the supervising physician survey in Ontario, Canada
por: Burrows, Kristen, et al.
Publicado: (2023)

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

Clinical outcome of adjuvant endocrine treatment according to Her-2/neu status in breast cancer
por: James, Rani, et al.
Publicado: (2011)

Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer: update of the Dutch randomized trial
por: Rodenhuis, S, et al.
Publicado: (2005)

Physician Career Choice and Satisfaction: Empirical Studies of Practicing Physicians
por: Pope, Barbara M.
Publicado: (2020)

Tiered Physician Network Plans and Patient Choices of Specialist Physicians
por: Prager, Elena, et al.
Publicado: (2023)

Critical appraisal skills of family physicians in Ontario, Canada
por: Godwin, Marshall, et al.
Publicado: (2003)

Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer
por: Wu, Yanyuan, et al.
Publicado: (2008)

Prognostic Value of KIF2A and HER2-Neu Overexpression in Patients With Epithelial Ovarian Cancer
por: Wang, Di, et al.
Publicado: (2016)

HER-2/neu diagnostics in breast cancer
por: Carney, Walter P, et al.
Publicado: (2007)

The Clinical Importance of the Heterogeneity of HER2 neu
por: Davila, Enrique, et al.
Publicado: (2010)

The New Physician to Her Majesty the Queen
Publicado: (1900)

Ontario family physicians’ perspectives about their scope of practice: what is it, what drives it and how does it change?
por: Myles, Sophia M., et al.
Publicado: (2022)

Social disparities in the use of colonoscopy by primary care physicians in Ontario
por: Jacob, Binu J, et al.
Publicado: (2011)

Physician snapshot: the forming landscape of MAiD in northwestern Ontario
por: Durant, Keri-Lyn, et al.
Publicado: (2020)

Societal Costs and Benefits of Treatment with Trastuzumab in Patients with Early HER2neu-Overexpressing Breast Cancer in Singapore
por: de Lima Lopes, Gilberto
Publicado: (2011)

Overexpression of miR-489 derails mammary hierarchy structure and inhibits HER2/neu-induced tumorigenesis
por: Patel, Y, et al.
Publicado: (2018)

The Physician's Guide to Chemotherapy
Publicado: (1955)

Choice is simply yours—Physician's perception
por: Dwivedi, Shridhar
Publicado: (2011)

Physician choices in pulmonary embolism testing
por: Zarabi, Sahar, et al.
Publicado: (2021)

Popularity of internet physician rating sites and their apparent influence on patients’ choices of physicians
por: Burkle, Christopher M., et al.
Publicado: (2015)

Defining hospitalist physicians using clinical practice data: a systems-level pilot study of Ontario physicians
por: White, Heather L., et al.
Publicado: (2013)

HER 2/neu protein expression in colorectal cancer
por: Schuell, B, et al.
Publicado: (2006)

HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma
por: Moelans, Cathy B., et al.
Publicado: (2010)

Anti-HER2/Neu passive-aggressive immunotherapy
por: Mortenson, Eric D, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_447abra6338ga0ftan2cips9rl